Tetracore Wins NIH Funds for Chikungunya/Dengue MDx on Its POC Thermocycler

Jan 30, 2015

|

Premium

NEW YORK (GenomeWeb) – Rockville, Md.-based diagnostics firm Tetracore has been awarded a one-year grant from the National Institute of Allergy and Infectious Diseases to develop a point-of-care, real-time reverse-transcriptase PCR assay that detects and distinguishes dengue and chikungunya viruses.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Breaking News

The Scan

The Poor P Value

A group of statisticians wants to eliminate researchers' reliance on 'statistical significance,' according to NPR.

Under the Watchful Smart Device Eye

Newsweek discusses the privacy issues raised by digital medicine.

This Week in Nature

In Nature this week: genetic analysis of Anatolian farmers, cotton genome analysis, and more.

Push for Predictive Genetic Tests

Matt Hancock, the UK health secretary, is calling for the swift rollout of predictive genetic tests, the Guardian reports.

Featured White Papers

Automated RT qPCR Utilizing the Access Workstation, the Echo Liquid Handler, and RealTime Ready Reagents from Roche Applied Science

High-throughput Miniaturized Quantitative PCR with the Echo 525 Liquid Handler

Miniaturization of the KASP Genotyping Assay for Maize with the Echo 525 Liquid Handler

Mar

27

Featured Webinar

How One NGS Core Lab Reduced Sequencing Costs with a Novel Library Normalization Kit

Sequencing workflows require library quantification and normalization to ensure data quality and reduce cost.

May

08

Featured Webinar

OncoBEAM ctDNA Testing for Early Response Prediction and Therapy Surveillance in Melanoma and Pancreatic Cancer

This webinar will present recent evidence that demonstrates how incorporating circulating tumor DNA (ctDNA) assessments into real-world patient management can influence patient care decisions, alter radiographic interpretations, and impact clinical outcomes.

Menu